What is the current Price Target for the Mineralys Therapeutics stock?

The average Mineralys Therapeutics target price is $45.39. This is 14.02% higher than the current stock price. The highest price target is 37.15%, the lowest is -34.04%. 10 Analysts have issued a price target Mineralys Therapeutics 2026 .

How high will the Mineralys Therapeutics stock rise?

No reliable answer can be given as to how high the Mineralys Therapeutics stock will rise. The performance of stocks, including the Mineralys Therapeutics stock, depends on a variety of factors, such as the general economic situation, the company's business results, investor expectations and global events.

What's going on with the Mineralys Therapeutics stock today?

The performance of Mineralys Therapeutics stock on any given day can be influenced by various factors, such as market conditions, industry trends, company news and global events.

Why did the Mineralys Therapeutics stock fall?

The decline in Mineralys Therapeutics stock may be due to a variety of factors, such as market conditions, industry trends, company news, macroeconomic events or changes in investor expectations. It is important to note that stock markets are inherently volatile and the performance of an individual stock on any given day is not necessarily indicative of its long-term performance.

What is a price target?

A price target is an estimate by an analyst or investment bank of where a company's stock price could be in a certain period of time, usually 12 months.

Mineralys Therapeutics Forecast, price target & analysts

$39.81

4.98% yesterday

NYSE, Oct 01, 10:09 pm CET

ISIN

US6031701013

Symbol

MLYS

Reports

Quarter | Annual

Sector

Pharmaceuticals, Biotechnology & Life Sciences

Industry

Biotechnology

Overview Dividends Analysts Charts News Strategies

Mineralys Therapeutics Target price 2025 - Analyst rating & recommendation

Mineralys Therapeutics Classifications & Recommendation:

Buy

87%

Hold

13%

Mineralys Therapeutics Price Target

Target Price	$45.39
Price	$39.81
Potential	14.02% register free of charge
Number of Estimates	10

	10 Analysts have issued a price target Mineralys Therapeutics 2026 . The average Mineralys Therapeutics target price is $45.39. This is 14.02% register free of charge higher than the current stock price. The highest price target is $54.60 37.15% register free of charge , the lowest is $26.26 34.04% register free of charge .
	A rating was issued by 15 analysts: 13 Analysts recommend Mineralys Therapeutics to buy, 2 to hold and 0 to sell.
	Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis.
	Analyst Estimates: Analysts believe that the Mineralys Therapeutics stock has an average upside potential 2026 of 14.02% register free of charge . Most analysts recommend the Mineralys Therapeutics stock at Purchase.

Earnings per share, P/E ratio and EV/sales Estimates 2025, 2026 to 2032

Create a premium account to unlock analyst estimates. Learn more

Annually

	Dec '24	2025 Estimates
Earnings Per Share $	-3.66	-2.80
	83.92%	23.50%
P/E		negative

10 Analysts have issued a Mineralys Therapeutics forecast for earnings per share. The average Mineralys Therapeutics EPS is

Unlock

. This is

Unlock

than earnings per share in the financial year 2024. The highest EPS forecast is

Unlock

, the lowest is

Unlock

This results in the following potential growth metrics and future valuations:

2024	$-3.66	83.92%
2025	$-2.80 23.50% Unlock
2026	$-2.71 3.21% Unlock
2027	$-3.14 15.87% Unlock
2028	$-1.28 59.24% Unlock
2029	$2.49 294.53% Unlock
2030	$5.14 106.43% Unlock
2031	$7.09 37.94% Unlock
2032	$8.76 23.55% Unlock

Current	-13.03	165.00%
2025	-13.56 4.06% Unlock
2026	-14.01 3.32% Unlock
2027	-12.06 13.92% Unlock
2028	-29.60 145.44% Unlock
2029	15.25 151.52% Unlock
2030	7.38 51.61% Unlock
2031	5.35 27.51% Unlock
2032	4.33 19.07% Unlock

Mineralys Therapeutics...

Current Mineralys Therapeutics Upgrades & Downgrades

Create a Premium account to unlock Upgrades/Downgrades. Learn more

Analyst	Rating	Action	Date
Wells Fargo	Locked ➜ Locked	Locked	Sep 11 2025
Goldman Sachs	Locked ➜ Locked	Locked	Sep 09 2025
HC Wainwright & Co.	Locked ➜ Locked	Locked	Sep 08 2025
Jefferies	Locked ➜ Locked	Locked	Sep 03 2025
B of A Securities	Locked ➜ Locked	Locked	Aug 28 2025
HC Wainwright & Co.	Locked ➜ Locked	Locked	Aug 13 2025
HC Wainwright & Co.	Locked ➜ Locked	Locked	Jun 17 2025

Analyst Rating	Date
Locked Wells Fargo: Locked ➜ Locked	Sep 11 2025
Locked Goldman Sachs: Locked ➜ Locked	Sep 09 2025
Locked HC Wainwright & Co.: Locked ➜ Locked	Sep 08 2025
Locked Jefferies: Locked ➜ Locked	Sep 03 2025
Locked B of A Securities: Locked ➜ Locked	Aug 28 2025
Locked HC Wainwright & Co.: Locked ➜ Locked	Aug 13 2025
Locked HC Wainwright & Co.: Locked ➜ Locked	Jun 17 2025

Discover more stocks with a high price target

TUI 45.53%

Novo Nordisk 39.14%

Adyen 36.82%

BioNTech SE - ADR 36.72%

Deutsche Telekom 32.79%

Meta Platforms (Facebook) 23.71%

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

Start now